Title |
Long‐term outcomes of a phase II randomized controlled trial comparing intensity‐modulated radiotherapy with or without weekly cisplatin for the treatment of locally recurrent nasopharyngeal carcinoma
|
---|---|
Published in |
Cancer Communications, February 2016
|
DOI | 10.1186/s40880-016-0081-7 |
Pubmed ID | |
Authors |
Ying Guan, Shuai Liu, Han-Yu Wang, Ying Guo, Wei-Wei Xiao, Chun-Yan Chen, Chong Zhao, Tai-Xiang Lu, Fei Han |
Abstract |
Salvage treatment for locally recurrent nasopharyngeal carcinoma (NPC) is complicated and relatively limited. Radiotherapy, combined with effective concomitant chemotherapy, may improve clinical treatment outcomes. We conducted a phase II randomized controlled trial to evaluate the efficacy of intensity-modulated radiotherapy with concomitant weekly cisplatin on locally recurrent NPC. Between April 2002 and January 2008, 69 patients diagnosed with non-metastatic locally recurrent NPC were randomly assigned to either concomitant chemoradiotherapy group (n = 34) or radiotherapy alone group (n = 35). All patients received intensity-modulated radiotherapy. The radiotherapy dose for both groups was 60 Gy in 27 fractions for 37 days (range 23-53 days). The concomitant chemotherapy schedule was cisplatin 30 mg/m(2) by intravenous infusion weekly during radiotherapy. The median follow-up period of all patients was 35 months (range 2-112 months). Between concomitant chemoradiotherapy and radiotherapy groups, there was only significant difference in the 3-year and 5-year overall survival (OS) rates (68.7% vs. 42.2%, P = 0.016 and 41.8% vs. 27.5%, P = 0.049, respectively). Subgroup analysis showed that concomitant chemoradiotherapy significantly improved the 5-year OS rate especially for patients in stage rT3-4 (33.0% vs. 13.2%, P = 0.009), stages III-IV (34.3% vs. 13.2%, P = 0.006), recurrence interval >30 months (49.0% vs. 20.6%, P = 0.017), and tumor volume >26 cm(3) (37.6% vs. 0%, P = 0.006). Compared with radiotherapy alone, concomitant chemoradiotherapy can improve OS of the patients with locally recurrent NPC, especially those with advanced T category (rT3-4) and stage (III-IV) diseases, recurrence intervals >30 months, and tumor volume >26 cm(3). |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 34 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Professor | 4 | 12% |
Student > Bachelor | 4 | 12% |
Student > Master | 4 | 12% |
Researcher | 4 | 12% |
Student > Postgraduate | 3 | 9% |
Other | 5 | 15% |
Unknown | 10 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 12 | 35% |
Nursing and Health Professions | 5 | 15% |
Biochemistry, Genetics and Molecular Biology | 2 | 6% |
Mathematics | 1 | 3% |
Agricultural and Biological Sciences | 1 | 3% |
Other | 3 | 9% |
Unknown | 10 | 29% |